Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides provided men with hemophilia B reliable relief from the bleeding disorder, paving the way for more active lifestyles
Gene therapy developed at St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital has transformed life for 10 men with severe hemophilia B.
St. Jude surgeons are world renowned for innovative approaches that save the lives of children with cancer and other diseases.
Exciting gene therapy study helps patients with hemophilia B.
Three decades after undergoing treatment at St. Jude, Katie Martin helps her daughter wage a similar battle.
Study of gene therapy developed at St. Jude Children’s Research Hospital and University College London offers first proof that the treatment benefits adults with hemophilia B; reduces need for clotting factor to prevent bleeds.
Vector-gene combination developed at St. Jude Children’s Research Hospital and UCL is central to latest clinical trial of gene therapy as a possible tool to provide long-term relief from disabling bleeds
The drug bevacizumab is widely used to inhibit blood vessel growth in tumors, starving them of oxygen and nutrients. St. Jude researchers have found that the drug also shows promise for attacking neuroblastoma cells themselves.
Some people compare it to a roller coaster ride. Others liken it to an interminable nightmare. But Tony McMorris describes his son’s journey through cancer treatment as an exhausting sprint with life-or-death odds. When doctors discovered softball-sized tumors on the kidneys of 1-year-old Brock McMorris, the race was on.
Children with bilateral Wilms tumor can retain normal function in both kidneys by undergoing a procedure called bilateral nephron-sparing surgery, even when preoperative scans suggest that the tumors are inoperable.
Helping blood vessels that feed a tumor become mature and healthy might not seem like the best strategy for ridding a patient of cancer. But researchers discovered that a previously unknown anti-tumor action for the molecule IFN-beta does just that.
St. Jude researchers showed in mouse models of neuroblastoma that a virus engineered to carry the gene for an anti-cancer protein is an effective treatment for this tumor that has fewer toxic side effects.
Surgeons, operating room nurses and anesthesiologists work together like a well-oiled machine to treat St. Jude patients.
Dr. Andrew Davidoff awarded ACGT Young Investigators national grant for work in the development of anti-angiogenic gene therapy for neuroblastoma, a deadly form of childhood cancer